| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| KRYSKrystal Biotech, Inc. | 8.18B | 282.01 | 94.00 | 473.02% | 53.3% | 17.48% | 1.46% | 0.01 |
| BMRNBioMarin Pharmaceutical Inc. | 10.58B | 55.07 | 24.92 | 17.97% | 16.82% | 8.59% | 4.49% | 0.11 |
| SRPTSarepta Therapeutics, Inc. | 2.23B | 21.31 | 9.11 | 52.97% | -11.25% | -20.57% | 0.88 | |
| RAREUltragenyx Pharmaceutical Inc. | 2.27B | 23.50 | -3.74 | 29.01% | -91.95% | -35.88% | 0.15 | |
| DYNDyne Therapeutics, Inc. | 2.7B | 16.42 | -4.87 | -61.26% | 0.04 | |||
| TVTXTravere Therapeutics, Inc. | 2.54B | 28.40 | -6.96 | 60.55% | -20.32% | -120.36% | 6.80 | |
| BEAMBeam Therapeutics Inc. | 3.25B | 32.05 | -7.00 | -83.18% | -7.44% | -42.92% | 0.22 | |
| SLNOSoleno Therapeutics, Inc. | 2.25B | 41.95 | -9.58 | -79.5% | -15.85% | 0.22 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 12.4M | 8.78M | 36.55M |
| Revenue Growth % | - | - | - | - | - | - | -0.29% | 3.16% |
| Cost of Goods Sold | 113K | 214K | 450K | 1.93M | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | -113K | -214K | -450K | -1.93M | 0 | 12.4M | 8.78M | 36.55M |
| Gross Margin % | - | - | - | - | - | 1% | 1% | 1% |
| Gross Profit Growth % | - | -0.89% | -1.1% | -3.28% | 1% | - | -0.29% | 3.16% |
| Operating Expenses | 5.55M | 12.78M | 35.23M | 51.12M | 86.06M | 116.76M | 123.55M | 137.93M |
| OpEx % of Revenue | - | - | - | - | - | 9.41% | 14.07% | 3.77% |
| Selling, General & Admin | 1.96M | 4.41M | 11.91M | 20.85M | 31.9M | 38.92M | 41.32M | 48.79M |
| SG&A % of Revenue | - | - | - | - | - | 3.14% | 4.71% | 1.33% |
| Research & Development | 3.6M | 8.37M | 23.31M | 32.2M | 54.17M | 77.84M | 82.23M | 89.13M |
| R&D % of Revenue | - | - | - | - | - | 6.27% | 9.37% | 2.44% |
| Other Operating Expenses | -4K | -10K | 0 | -1.93M | 0 | 0 | 0 | 0 |
| Operating Income | -5.55M | -12.78M | -35.68M | -53.04M | -86.06M | -104.36M | -114.77M | -101.37M |
| Operating Margin % | - | - | - | - | - | -8.41% | -13.07% | -2.77% |
| Operating Income Growth % | - | -1.3% | -1.79% | -0.49% | -0.62% | -0.21% | -0.1% | 0.12% |
| EBITDA | -5.44M | -12.57M | -35.23M | -51.12M | -85.09M | -102.81M | -112.3M | -99.19M |
| EBITDA Margin % | - | - | - | - | - | -8.29% | -12.79% | -2.71% |
| EBITDA Growth % | - | -1.31% | -1.8% | -0.45% | -0.66% | -0.21% | -0.09% | 0.12% |
| D&A (Non-Cash Add-back) | 113K | 214K | 450K | 1.93M | 974K | 1.55M | 2.47M | 2.18M |
| EBIT | -5.55M | -12.78M | -32.33M | -52.24M | -86.06M | -104.36M | -114.77M | -101.37M |
| Net Interest Income | 0 | 0 | 3.35M | 744K | 120K | 0 | 0 | 0 |
| Interest Income | 0 | 270K | 3.35M | 744K | 120K | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -4K | 260K | 3.35M | 801K | 260K | 3.29M | 10.07M | 12.39M |
| Pretax Income | -5.56M | -12.52M | -32.33M | -52.24M | -85.81M | -101.07M | -104.7M | -88.98M |
| Pretax Margin % | - | - | - | - | - | -8.15% | -11.92% | -2.43% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -5.56M | -12.52M | -32.33M | -52.24M | -85.81M | -101.07M | -104.7M | -88.98M |
| Net Margin % | - | - | - | - | - | -8.15% | -11.92% | -2.43% |
| Net Income Growth % | - | -1.25% | -1.58% | -0.62% | -0.64% | -0.18% | -0.04% | 0.15% |
| Net Income (Continuing) | -5.56M | -12.52M | -32.33M | -52.24M | -85.81M | -101.07M | -104.7M | -88.98M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.24 | -0.53 | -1.59 | -1.56 | -2.34 | -2.60 | -2.38 | -1.65 |
| EPS Growth % | - | -1.21% | -2% | 0.02% | -0.5% | -0.11% | 0.08% | 0.31% |
| EPS (Basic) | -0.24 | -0.53 | -1.59 | -1.56 | -2.34 | -2.60 | -2.38 | -1.65 |
| Diluted Shares Outstanding | 23.51M | 23.51M | 17.97M | 33.49M | 36.74M | 38.9M | 43.99M | 54.01M |
| Basic Shares Outstanding | 23.51M | 23.51M | 17.97M | 33.49M | 36.74M | 38.9M | 43.99M | 54.01M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 1.91M | 106.14M | 226.03M | 293.93M | 229.22M | 244.07M | 215.34M | 232.76M |
| Cash & Short-Term Investments | 1.8M | 105.4M | 222.47M | 287.31M | 219.81M | 229.59M | 201.39M | 216.9M |
| Cash Only | 1.8M | 105.4M | 222.47M | 287.31M | 144.9M | 113.56M | 191.44M | 127.98M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 74.92M | 116.04M | 9.95M | 88.92M |
| Accounts Receivable | 0 | 196K | 281K | 6K | 132K | 588K | 64K | 700K |
| Days Sales Outstanding | - | - | - | - | - | 17.3 | 2.66 | 6.99 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 181K | 2.33M | 2.96M | 2.56M | 4.04M |
| Total Non-Current Assets | 529K | 1.4M | 2.72M | 4M | 9.65M | 12M | 13M | 38.8M |
| Property, Plant & Equipment | 473K | 1.19M | 2.51M | 3.79M | 9.08M | 11.43M | 12.43M | 8.25M |
| Fixed Asset Turnover | - | - | - | - | - | 1.09x | 0.71x | 4.43x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 56K | 204K | 0 | 0 | 0 | 0 | 0 | 29.82M |
| Other Non-Current Assets | 0 | 0 | 205K | 205K | 569K | 569K | 569K | 721K |
| Total Assets | 2.44M | 107.54M | 228.75M | 297.93M | 238.87M | 256.07M | 228.34M | 271.56M |
| Asset Turnover | - | - | - | - | - | 0.05x | 0.04x | 0.13x |
| Asset Growth % | - | 43.09% | 1.13% | 0.3% | -0.2% | 0.07% | -0.11% | 0.19% |
| Total Current Liabilities | 3.71M | 2.47M | 4.1M | 11.43M | 17.14M | 31.39M | 30.82M | 40.06M |
| Accounts Payable | 141K | 1.07M | 751K | 1.5M | 2.38M | 766K | 1.7M | 2.5M |
| Days Payables Outstanding | 455.44 | 1.83K | 609.14 | 283.32 | - | - | - | - |
| Short-Term Debt | 3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | -1000K | 0 | 0 | 0 | 0 | 1000K | 1000K | 1000K |
| Other Current Liabilities | 0 | 0 | 2.11M | 4.58M | 5.92M | 6.26M | 6.47M | 8.44M |
| Current Ratio | 0.51x | 43.03x | 55.12x | 25.73x | 13.37x | 7.77x | 6.99x | 5.81x |
| Quick Ratio | 0.51x | 43.03x | 55.12x | 25.73x | 13.37x | 7.77x | 6.99x | 5.81x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 16K | 4K | 221K | 422K | 3.95M | 39.82M | 37.96M | 2.48M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 16K | 4K | 221K | 422K | 3.95M | 2.97M | 4.88M | 2.48M |
| Total Liabilities | 3.73M | 2.47M | 4.32M | 11.85M | 21.09M | 71.22M | 68.78M | 42.53M |
| Total Debt | 3M | 0 | 0 | 1.07M | 1.51M | 2.36M | 2.06M | 2.32M |
| Net Debt | 1.2M | -105.4M | -222.47M | -286.24M | -143.39M | -111.2M | -189.38M | -125.66M |
| Debt / Equity | - | - | - | 0.00x | 0.01x | 0.01x | 0.01x | 0.01x |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - |
| Total Equity | -1.29M | 105.07M | 224.43M | 286.08M | 217.78M | 184.85M | 159.56M | 229.02M |
| Equity Growth % | - | 82.32% | 1.14% | 0.27% | -0.24% | -0.15% | -0.14% | 0.44% |
| Book Value per Share | -0.05 | 4.47 | 12.49 | 8.54 | 5.93 | 4.75 | 3.63 | 4.24 |
| Total Shareholders' Equity | -1.29M | 105.07M | 224.43M | 286.08M | 217.78M | 184.85M | 159.56M | 229.02M |
| Common Stock | 1K | 1K | 3K | 4K | 4K | 4K | 5K | 5K |
| Retained Earnings | -13.19M | -25.71M | -58.03M | -110.28M | -196.08M | -297.15M | -401.85M | -490.83M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -172K | -379K | 0 | 0 | -168K | -1.18M | -24K | -151K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -5.38M | -10.96M | -31.05M | -42.22M | -66.91M | -31.87M | -81.07M | -86.85M |
| Operating CF Margin % | - | - | - | - | - | -2.57% | -9.23% | -2.38% |
| Operating CF Growth % | - | -1.04% | -1.83% | -0.36% | -0.58% | 0.52% | -1.54% | -0.07% |
| Net Income | -5.56M | -12.52M | -32.33M | -52.24M | -85.81M | -101.07M | -104.7M | -88.98M |
| Depreciation & Amortization | 113K | 214K | 450K | 888K | 974K | 1.55M | 2.47M | 2.18M |
| Stock-Based Compensation | 26K | 240K | 1.92M | 5.77M | 16.45M | 22.85M | 25.26M | 27.47M |
| Deferred Taxes | 0 | 0 | 0 | 3K | 172K | 0 | 0 | 0 |
| Other Non-Cash Items | 4K | 10K | 3K | 1.04M | 1.26M | 1.78M | 1.94M | 623K |
| Working Capital Changes | 31K | 1.09M | -1.1M | 2.33M | 46K | 43.02M | -6.03M | -28.14M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 100K | 1.74M | 891K | 5.2M | 2.9M | 121K | -3.21M | 3.09M |
| Cash from Investing | -113K | -925K | -1.63M | -1.05M | -76.43M | -45.88M | 105.95M | -107.47M |
| Capital Expenditures | -113K | -935K | -1.64M | -1.05M | -1.2M | -3.96M | -1.62M | -203K |
| CapEx % of Revenue | - | - | - | - | - | 0.32% | 0.18% | 0.01% |
| Acquisitions | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 10K | 0 | 0 | -75.23M | -45.34M | 0 | 0 |
| Cash from Financing | 5.97M | 115.64M | 149.76M | 108.11M | 1.28M | 46.41M | 53.01M | 131.09M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - |
| Other Financing | 2.97M | -361K | -2.15M | 2.71M | -2K | 1.06M | 926K | 2.25M |
| Net Change in Cash | - | - | - | - | - | - | - | - |
| Free Cash Flow | -5.5M | -11.9M | -32.69M | -43.27M | -68.11M | -35.83M | -82.68M | -87.05M |
| FCF Margin % | - | - | - | - | - | -2.89% | -9.42% | -2.38% |
| FCF Growth % | - | -1.16% | -1.75% | -0.32% | -0.57% | 0.47% | -1.31% | -0.05% |
| FCF per Share | -0.23 | -0.51 | -1.82 | -1.29 | -1.85 | -0.92 | -1.88 | -1.61 |
| FCF Conversion (FCF/Net Income) | 0.97x | 0.88x | 0.96x | 0.81x | 0.78x | 0.32x | 0.77x | 0.98x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -24.13% | -19.62% | -20.47% | -34.06% | -50.2% | -60.8% | -45.8% |
| Return on Invested Capital (ROIC) | - | - | -3291.33% | -4437.59% | -173.93% | -105.74% | -392.73% | -206.76% |
| Gross Margin | - | - | - | - | - | 100% | 100% | 100% |
| Net Margin | - | - | - | - | - | -814.73% | -1192.47% | -243.42% |
| Debt / Equity | - | - | - | 0.00x | 0.01x | 0.01x | 0.01x | 0.01x |
| FCF Conversion | 0.97x | 0.88x | 0.96x | 0.81x | 0.78x | 0.32x | 0.77x | 0.98x |
| Revenue Growth | - | - | - | - | - | - | -29.22% | 316.34% |
| 2024 | |
|---|---|
| License | 29.4M |
| License Growth | - |
| Service | 7.2M |
| Service Growth | - |
Stoke Therapeutics, Inc. (STOK) reported $205.6M in revenue for fiscal year 2024.
Stoke Therapeutics, Inc. (STOK) grew revenue by 316.3% over the past year. This is strong growth.
Yes, Stoke Therapeutics, Inc. (STOK) is profitable, generating $40.6M in net income for fiscal year 2024 (-243.4% net margin).
Stoke Therapeutics, Inc. (STOK) has a return on equity (ROE) of -45.8%. Negative ROE indicates the company is unprofitable.
Stoke Therapeutics, Inc. (STOK) generated $52.4M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.